{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:27:05Z","timestamp":1783117625933,"version":"3.54.6"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Premature ejaculation (PE) is the most common male sexual dysfunction. Dapoxetine hydrochloride, belonging to a class of drugs known as selective serotonin reuptake inhibitors or, was the first drug originally approved for the on-demand treatment of men with PE. We aimed to compare the intravaginal ejaculatory latency time (IELT), patient-reported global impression of change (PGIC) and adverse effect (AE) incidence associated with the use of dapoxetine (30\u2005mg and 60\u2005mg) versus placebo and evaluate the differences in administering 60\u2005mg versus 30\u2005mg as on-demand medical oral therapy for the treatment of PE via a literature review and meta-analysis. Relevant randomized controlled trials (RCTs) were identified from PubMed, EMBASE and Cochrane Central Register of Controlled Trials (Cochrane Library) databases. Ultimately, a total of seven RCTs with 8039 patients were included. Our meta-analysis demonstrated that dapoxetine (in the 30\u2005mg and 60\u2005mg subgroup) resulted in significantly higher IELT, PGIC and AE incidence relative to the placebo, with higher proportions observed for 60\u2005mg versus 30\u2005mg of dapoxetine administration. The most common AEs were mild and tolerable. We conclude that dapoxetine (particularly the 60\u2005mg dosage) may be considered a safe and effective drug for patients with PE.<\/jats:p>","DOI":"10.1038\/srep07269","type":"journal-article","created":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T10:23:09Z","timestamp":1417429389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The role of dapoxetine hydrochloride on-demand for the treatment of men with premature ejaculation"],"prefix":"10.1038","volume":"4","author":[{"given":"Cao","family":"De Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu Liang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,1]]},"reference":[{"key":"BFsrep07269_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/sj.ijir.3901250","volume":"17","author":"EO Laumann","year":"2005","unstructured":"Laumann, E. O. et al. Sexual problems among women and men aged 40\u201380 y: prevalence and correlates identified in the global study of sexual attitudes and behaviors. Int J Impot Res 17, 39\u201357 (2005).","journal-title":"Int J Impot Res"},{"key":"BFsrep07269_CR2","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.eururo.2006.07.004","volume":"51(3)","author":"H Porst","year":"2007","unstructured":"Porst, H. et al. The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities and professional help-seeking. Eur Urol 51(3), 816\u2013823 (2007).","journal-title":"Eur Urol"},{"key":"BFsrep07269_CR3","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1111\/jsm.12504","volume":"11","author":"SE Althof","year":"2014","unstructured":"Althof, S. E. et al. An update of the international society of sexual medicine's guidelines for the diagnosis and treatment of premature ejaculation (PE). J Sex Med 11, 1392\u20131422 (2014).","journal-title":"J Sex Med"},{"key":"BFsrep07269_CR4","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/j.1464-410X.2008.07755.x","volume":"102","author":"CG Mcmahon","year":"2008","unstructured":"Mcmahon, C. G. et al. An evidence-base definition of lifelong premature ejaculation: report of the internation society for sexual medicine ad hoc committee for the definition of premature ejaculation. BJU Int 102, 338\u2013350 (2008).","journal-title":"BJU Int"},{"key":"BFsrep07269_CR5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/00926230390224738","volume":"29","author":"T Symonds","year":"2003","unstructured":"Symonds, T., Roblin, D., Hart, K. & Althof, S. How does premature ejaculation impact a man's life? J Sex Marital Ther 29, 361\u2013370 (2003).","journal-title":"J Sex Marital Ther"},{"key":"BFsrep07269_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11930-014-0014-x","volume":"6","author":"GC Bailey","year":"2014","unstructured":"Bailey, G. C. & Trost, L. W. Current diagnosis and management of premature ejaculation. Curr Sex Health Rep 6, 65\u201380 (2014).","journal-title":"Curr Sex Health Rep"},{"key":"BFsrep07269_CR7","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.eururo.2010.02.020","volume":"57","author":"K Hatzimouratidis","year":"2010","unstructured":"Hatzimouratidis, K. et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 57, 804\u2013814 (2010).","journal-title":"Eur Urol"},{"key":"BFsrep07269_CR8","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1038\/sj.ijir.3901507","volume":"18 Suppl 1","author":"C Carson","year":"2006","unstructured":"Carson, C. & Gunn, K. Premature ejaculation: definition and prevalence. Int J Impot Res 18 Suppl 1, S5\u201313 (2006).","journal-title":"Int J Impot Res"},{"key":"BFsrep07269_CR9","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0140-6736(06)69373-2","volume":"368","author":"JL Pryor","year":"2006","unstructured":"Pryor, J. L. et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomized controlled trials. Lancet 368, 929\u2013937 (2006).","journal-title":"Lancet"},{"key":"BFsrep07269_CR10","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/j.1464-410X.2008.08165.x","volume":"103","author":"JM Kaufman","year":"2008","unstructured":"Kaufman, J. M. et al. Treatment benefit of dapoxetine for premature ejaculation: result from a placebo-controlled phase III trial. BJU Int 103, 651\u2013658 (2008).","journal-title":"BJU Int"},{"key":"BFsrep07269_CR11","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/j.1464-410X.2008.07845.x","volume":"102","author":"R Shabsigh","year":"2008","unstructured":"Shabsigh, R. et al. Perceived control over ejaculation is central to treatment benefit in men with premature ejaculation: results from phase III trials with dapoxetine. BJU Int 102, 824\u2013828 (2008).","journal-title":"BJU Int"},{"key":"BFsrep07269_CR12","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.eururo.2009.01.025","volume":"55","author":"J Buvat","year":"2009","unstructured":"Buvat, J., Tesfaye, F., Rothman, M., Rivas, D. A., Giuliano, F. et al. Dapoxetine for the Treatment of Premature Ejaculation: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 trial in 22 Countries. Eur Urol 55, 957\u2013968 (2009).","journal-title":"Eur Urol"},{"key":"BFsrep07269_CR13","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1743-6109.2009.01560.x","volume":"7","author":"C McMahon","year":"2010","unstructured":"McMahon, C. et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. J Sex Med 7, 256\u2013268 (2010).","journal-title":"J Sex Med"},{"key":"BFsrep07269_CR14","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/j.1365-2605.2011.01243.x","volume":"35","author":"AL Pastore","year":"2012","unstructured":"Pastore, A. L. et al. A prospective randomized study to compare pelvic floor rehabilitation and dapoxetine for treatment of lifelong premature ejaculation. Int J Androl 35, 528\u2013533 (2012).","journal-title":"Int J Androl"},{"key":"BFsrep07269_CR15","doi-asserted-by":"crossref","unstructured":"Simsek, A. et al. Comparison of paroxetine and dapoxetine, a novel selective serotonin reuptake inhibitor in the treatment of premature ejaculation. Asian J Androl (2014) [Epub ahead of print]. 10.4103\/1008-682X.128467.","DOI":"10.4103\/1008-682X.128467"},{"key":"BFsrep07269_CR16","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1743-6109.2010.02097.x","volume":"8","author":"CG McMahon","year":"2011","unstructured":"McMahon, C. G. et al. Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials. J Sex Med 8, 524\u2013539 (2011).","journal-title":"J Sex Med"},{"key":"BFsrep07269_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/CE.S13841","volume":"7","author":"EJ McCarty","year":"2012","unstructured":"McCarty, E. J. & Dinsmore, W. W. Dapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculation. Core Evidence 7, 1\u201314 (2012).","journal-title":"Core Evidence"},{"key":"BFsrep07269_CR18","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1111\/jsm.12236","volume":"10","author":"CG McMahon","year":"2013","unstructured":"McMahon, C. G. et al. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. J Sex Med 10, 2312\u20132325 (2013).","journal-title":"J Sex Med"},{"key":"BFsrep07269_CR19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.eururo.2013.08.018","volume":"65","author":"V Mirone","year":"2014","unstructured":"Mirone, V. et al. Results from a prospective observational study of men with premature ejaculation treated with dapoxetine or alternative care: the pause study. Euro Urol 65, 733\u2013739 (2014).","journal-title":"Euro Urol"},{"key":"BFsrep07269_CR20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/01.WNF.0000228210.12194.46","volume":"29","author":"MR Safarinejad","year":"2006","unstructured":"Safarinejad, M. R. Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: A double-blind, placebocontrolled, fixed-dose, randomized study. Clin Neuropharmacol 29, 243\u2013252 (2006).","journal-title":"Clin Neuropharmacol"},{"key":"BFsrep07269_CR21","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1038\/sj.npp.1301500","volume":"33","author":"MR Safarinejad","year":"2008","unstructured":"Safarinejad, M. R. Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology 33, 1259\u20131265 (2008).","journal-title":"Neuropsychopharmacology"},{"key":"BFsrep07269_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/1756287211424172","volume":"3(5)","author":"A Mohee","year":"2011","unstructured":"Mohee, A. & Eardley, I. Medical therapy for premature ejaculation. Ther Adv Urol 3(5), 211\u2013222 (2011).","journal-title":"Ther Adv Urol"},{"key":"BFsrep07269_CR23","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1743-6109.2011.02451.x","volume":"8 suppl 4","author":"H Porst","year":"2011","unstructured":"Porst, H. An overview of pharmacotherapy in premature ejaculation. J Sex Med 8 suppl 4, 335\u2013341 (2011).","journal-title":"J Sex Med"},{"key":"BFsrep07269_CR24","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/0091270005284850","volume":"46","author":"NB Modi","year":"2006","unstructured":"Modi, N. B. et al. Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol 46, 301\u2013309 (2006).","journal-title":"J Clin Pharmacol"},{"key":"BFsrep07269_CR25","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1111\/jsm.12287","volume":"10","author":"WK Lee","year":"2013","unstructured":"Lee, W. K. et al. Comparison between on-demand dosing of dapoxetine alone and dapoxetine plus mirodenafil in patients with lifelong premature ejaculation: prospective, randomized, double-blind, placebo-controlled, multicenter study. J Sex Med 10, 2832\u20132841 (2013).","journal-title":"J Sex Med"},{"key":"BFsrep07269_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.urology.2011.09.031","volume":"79","author":"M Kaynar","year":"2012","unstructured":"Kaynar, M., Kilic, O. & Yurdakul, T. On-demand tramadol hydrochloride use in premature ejaculation treatment. Urology 79, 145\u2013149 (2012).","journal-title":"Urology"},{"key":"BFsrep07269_CR27","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1111\/j.1743-6109.2010.01793.x","volume":"7(6)","author":"SE Althof","year":"2010","unstructured":"Althof, S. E. et al. Validity of the patient-reported Clinical Global Impression of Change as a measure of treatment response in men with premature ejaculation. J Sex Med 7(6), 2243\u20132252 (2010).","journal-title":"J Sex Med"},{"key":"BFsrep07269_CR28","unstructured":"Higgins, J. & Green, S. Cochrane Handbook For Systematic Review Of Intervention 5.1.0. (The Nordic Cochrane Centre, Copenhagen, 2011)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep07269.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep07269","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep07269.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T06:04:33Z","timestamp":1672985073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep07269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,1]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,12,17]]}},"alternative-id":["BFsrep07269"],"URL":"https:\/\/doi.org\/10.1038\/srep07269","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,1]]},"assertion":[{"value":"19 September 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7269"}}